60 Degrees Pharmaceuticals (SXTP) announced the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study. The B-FREE study, the first in the world to evaluate a potential new therapeutic for chronic babesiosis, will run for approximately 12 months. It is a Phase 2 open-label study that will evaluate the efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days for resolution of severe fatigue, and parasite eradication in patients with chronic babesiosis, a potentially disabling condition carried by the same tick that spreads Lyme disease.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals Highlights ARAKODA Growth Potential
- 60 Degrees Pharmaceuticals Enters New Sales Agreement
- 60 Degrees selects Icahn School of Medicine as central site for Phase II study
- 60 Degrees Pharmaceuticals Reports Q2 2025 Earnings
- SXTP Earnings Report this Week: Is It a Buy, Ahead of Earnings?